Radar · Metabolic Diseases in United States
Best Metabolic Diseases Companies in United States
The 296 best Metabolic Diseases companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nimbus Therapeutics.
By Riya SenguptaFinancials
296companies tracked
$14.3Bdisclosed funding
1unicorns
184have raised
Ranked by disclosed equity funding across 296 tracked companies, this directory captures the Metabolic Diseases funding landscape in the United States with more precision than most deal trackers bother to attempt. $14.3 billion in total disclosed capital. One unicorn. And a cohort of lead filers whose numbers tell you exactly where conviction is sitting right now.
Kriya Therapeutics has pulled in $618 million, Enveda sits at $505 million, and Kailera has secured $400 million, the kind of figures that signal long-duration bets on gene therapy and rare-disease biology, not incremental pipeline shuffles. I'd note that the investor roster here, RA Capital Management, Frazier Healthcare Partners, Orbimed, backs that read: these are funds that price science hard before they write checks. So what does the sector's momentum actually look like beneath those headline rounds? Coverage is rising, and the hot themes pulling capital are neglected tropical diseases, gene therapy for rare conditions, and international disease burden, including malaria. If you're mapping where Metabolic Diseases investment in the United States is heading, the directory below gives you the disclosed funding and recent momentum to make that call on real numbers.
Ranked: Best Metabolic Diseases companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nimbus Therapeutics Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 33 mo ago | 81 81 → 99 (+22%) · sector median +32% | Jeb Keiper CEO | WordPressApple iCloud MailMySQL+14 | — | — | — |
| 2 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | WordPress Site EditorWordPressMySQL+12 | 5 signals Funding · Capital raise · Leadership | — | — |
| 3 | Enveda 🦄 AI-based platform to decipher the chemistry of nature and develop new medicines 72Funding top 12%Moat top 32%Growth top 35%Market top 44% All 8 signals ▾Fundingtop 12% Moattop 32% Growthtop 35% Markettop 44% AItop 45% Talentbottom 49% Globalbottom 48% Techbottom 46% Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Moat: Unicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 72/100 | $505M | 9 mo ago | — | Viswa Colluru Founder & CEO | WordPressApple iCloud MailMySQL+22 | — | — | — |
| 4 | Carmot Developer of disease-modifying therapies to treat metabolic diseases | $401M | 36 mo ago | 50 | Heather Turner CEO | — | — | — | — |
| 5 | Kailera Developer of therapies for treating obesity and related conditions 60Funding top 12%Growth top 20%News top 22%Moat top 31% All 8 signals ▾Fundingtop 12% Growthtop 20% Newstop 22% Moattop 31% Techtop 40% Talentbottom 41% Globalbottom 38% Marketbottom 36% Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $400M | 8 mo ago | — | Ron Renaud Founder & CEO | DrupalApple iCloud MailPHP+27 | 6 signals IPO · Leadership | — | 1 internship |
| 6 | NGM Biopharmaceuticals Developer of biologics for the treatment of cardio-metabolic and liver disease | $359M | 23 mo ago | 225 | — | — | — | 659 patents Therapeutic antibodies and peptide drugs targeting ILT, glucagon, and GFRAL receptors | — |
| 7 | Fractyl Provider of Endoscopic procedure for type - 2 diabetes | $345M | 60 mo ago | 79 79 → 106 (+34%) · sector median +32% | Jay Caplan Co-founder and President | WordPressApple iCloud MailMicrosoft 365+28 | 8 signals ▲300% Leadership · Earnings | — | — |
| 8 | CORXEL Developer of therapies for patients with cardiometabolic conditions | $287M | 4 mo ago | — | Sandy Mou CEO | GSAPCloudflare Rocket LoaderSwiper+8 | — | — | — |
| 9 | Rivus Pharmaceuticals Developer of therapeutics for cardio-metabolic disorders | $233M | 17 mo ago | 12 | Allen Cunningham CEO | — | — | — | 1 launch |
| 10 | Aligos Therapeutics Developer of therapies to treat hepatologic diseases and viral infections 50Patents top 12%Innovation top 16%Funding top 26%Moat top 35% All 12 signals ▾Patentstop 12% Innovationtop 16% Fundingtop 26% Moattop 35% Partnerstop 40% Techtop 42% Talenttop 45% Globaltop 46% Newstop 47% Marketbottom 46% Growthbottom 32% Fin. healthbottom 25% Patents: 503 patents matched (strict assignee match) · 389 filings since 2022 vs 114 in 2017-21 Innovation: 503 patents (top 5% of patent-holders) · 389 filings since 2022 vs 114 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $225M | 16 mo ago | 70 70 → 99 (+41%) · sector median +32% | Lawrence Blatt CEO | DrupalApple iCloud MailPHP+21 | 8 signals ▼65% Earnings · Contracts | 503 patents RNA interference therapeutics and PD‑L1 immuno‑oncology using heterocyclic siRNA delivery compounds | — |
| 11 | MBX Biosciences Developer of drugs for the treatment of rare endocrine diseases | $216M | 22 mo ago | 11 | Kent Hawryluk President & CEO | WordPressMySQLPHP+22 | 7 signals Earnings · Announcements · Leadership | — | 1 partnership |
| 12 | Tenvie Developer of small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases | $200M | 17 mo ago | — | Brian Cuneo Co-Founder & CLO | — | — | — | 4 job openings |
| 13 | Metabolon Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine | $173M | 16 mo ago | 189 189 → 203 (+7%) · sector median +32% | — | WordPressApple iCloud MailMicrosoft 365+39 | — | 400 patents Metabolomics-based biomarker discovery and diagnostic assays for metabolic and inflammatory diseases. | — |
| 14 | Renibus Therapeutics Provider of therapeutics to treat kidney diseases | $154M | 36 mo ago | 19 | Jeff Keyser Co-Founder | WordPressMySQLPHP+19 | — | — | — |
| 15 | OrsoBio Developer of therapeutics for multiple metabolic diseases | $152M | 15 mo ago | 10 | — | WordPressMySQLPHP+15 | — | 45 patents Small-molecule LXR modulators and ACMSD inhibitors for dyslipidemia and metabolic disease therapy | — |
| 16 | Allurion Developer of Gastric Balloon device for weight loss management 50Funding top 22%Customers top 23%Product top 24%Tech top 26% All 13 signals ▾Fundingtop 22% Customerstop 23% Producttop 24% Techtop 26% Moattop 38% Markettop 40% Innovationtop 50% Talentbottom 49% Patentsbottom 42% Globalbottom 42% Newsbottom 36% Fin. healthbottom 35% Growthbottom 29% Funding: Raised $151M across 15 rounds · 15 rounds over 14 yrs (1.1/yr) Customers: Play-Store rating 4.75★ across 1,421 ratings (1 apps) · Review volume +53% in 6 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $151M | 7 mo ago | 252 | Samuel Levy Founder | DrupalApple iCloud MailPHP+31 | — | 38 patents Temporary intragastric implant deployment systems for minimally invasive obesity treatment | 1 award |
| 17 | Judo Bio Developer of therapeutics for systemic and renal diseases | $150M | 20 mo ago | — | Rajiv Patni CEO | WordPressMySQLPHP+15 | — | — | 1 job opening |
| 18 | Arthrosi Therapeutics Developer of therapeutics for gout, chronic kidney diseases, and oncology 22Funding top 26%News top 46%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 26% Newstop 46% Moattop 48% Talentbottom 49% Techbottom 43% Globalbottom 37% Marketbottom 24% Funding: Raised $140M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) News: 2 BI events in 12 mo (of 6 tracked, 3 types) · +100% YoY rank vs industry peers · Fliar Intelligence Index 22/100 | $140M | 12 mo ago | 11 | Litain Yeh Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+24 | — | — | — |
| 19 | Cour Pharma Developer of biotech nano-particles for immune diseases | $135M | 28 mo ago | 31 | John Puisis Founder | — | — | — | — |
| 20 | MeiraGTx Developer of gene therapies for ocular and neurodegenerative diseases | $130M | 31 mo ago | 358 358 → 419 (+17%) · sector median +32% | — | DrupalApple iCloud MailPHP+26 | 3 signals ▼73% Earnings | 14 patents Therapeutic modulation of the retromer complex for neurodegenerative disease treatment | — |
| 21 | Mirum Pharmaceuticals Developer of small molecule based therapeutics to treat rare diseases 82Funding top 17%Patents top 18%Innovation top 23%Product top 28% All 12 signals ▾Fundingtop 17% Patentstop 18% Innovationtop 23% Producttop 28% Growthtop 30% Fin. healthtop 31% Markettop 33% Moattop 35% Newstop 36% Techtop 45% Talentbottom 49% Globalbottom 47% Funding: Raised $120M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) Patents: 135 patents matched (strict assignee match) · 115 filings since 2022 vs 20 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $120M | 4 mo ago | 196 196 → 465 (+137%) · sector median +32% | Christopher Peetz CEO | WordPressMySQLPHP+18 | 24 signals Announcements · Earnings · M&A | 135 patents IBAT inhibitor drugs for treating cholestasis and pediatric liver disease | — |
| 22 | Axial Therapeutics Developer of small molecule therapeutics for central nervous system disorder | $110M | 16 mo ago | 12 12 → 12 (+0%) · sector median +32% | A Campbell CEO | — | — | — | — |
| 23 | Crinetics Developer of therapies for the treatment of endocrine-related diseases and cancers | $104M | 27 mo ago | 120 | Scott Struthers Founder | WordPressApple iCloud MailMicrosoft 365+33 | 16 signals ▼47% Announcements · Earnings · FDA approval | — | — |
| 24 | Ambagon Developer of small-molecule therapeutics for the treatment of cancer | $103M | 16 mo ago | 49 | Luc Brunsveld Co-Founder | WordPressMySQLPHP+20 | — | — | — |
| 25 | Akebia Therapeutics Developing therapeutics solutions to treat patients with kidney disease | $91M | 28 mo ago | 205 205 → 264 (+29%) · sector median +32% | John Butler President and CEO | WordPressApple iCloud MailMySQL+23 | 11 signals Announcements · Earnings | 539 patents Therapeutic small‑molecule drugs for anemia, complement inhibition, and related disease treatments | — |
| 26 | Cirius Therapeutics Developer of therapeutics to treat liver and metabolic diseases | $75M | 8 mo ago | 11 | — | — | — | — | — |
| 27 | DermBiont Developer of microbial therapeutics designed to treat skin diseases | $73M | 32 mo ago | 36 | Nichola Eliovits Co-Founder | Squarespace CommerceSquarespaceTypeScript+16 | — | 49 patents Topical PK/AKT inhibitor formulations for treating and preventing skin disorders | — |
| 28 | Marea Therapeutics Provider of therapeutics for cardiometabolic diseases | $65M | 24 mo ago | — | Stephen Rahilly Co-Founder | — | — | — | — |
| 29 | Diasome Developer of therapies for the treatment of diabetes and other metabolic conditions | $60M | 22 mo ago | 7 | W Blair Geho Founder & Director | — | — | — | 1 launch |
| 30 | i2o Therapeutics Provider of an oral drug delivery solution | $54M | 32 mo ago | 6 | Samir Mitragotri Co-Founder | — | — | — | — |
| 31 | Spruce Developer of therapies for rare endocrine disorders | $50M | 8 mo ago | 29 | Javier Szwarcberg CEO | WordPressMySQLPHP+25 | — | 5 patents Patents concentrated in electrical & electronics | — |
| 32 | VTV Therapeutics Developer of small molecules for diabetes, muscle weakness and inflammatory diseases | $49M | 27 mo ago | 22 | Paul Sekhri Chairman | DrupalPHPAmazon Web Services+21 | 3 signals ▼75% Earnings | 321 patents Small-molecule therapeutics for metabolic, neurodegenerative, and bone disease targets | — |
| 33 | Siolta Therapeutics Provider of microbiome therapeutics for treating multiple diseases | $42M | 27 mo ago | 14 | Nikole Kimes Founder & CEO | — | — | — | — |
| 34 | Think Bioscience Provider of synthetic biology platform to develop small-molecule therapeutics 22Funding top 30%Talent top 38%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 30% Talenttop 38% Moattop 39% Globalbottom 39% Techbottom 30% Marketbottom 28% Funding: Raised $26.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 22/100 | $26M | 4 mo ago | 21 21 → 31 (+48%) · sector median +32% | Jerome Fox Co-Founder & CEO | WordPressMySQLPHP+11 | — | — | — |
| 35 | Secretome Therapeutics Developer of cell-based therapies for multiple diseases | $22M | 0 mo ago | 8 | Sudhish Sharma Co-Founder | WordPressMySQLPHP+14 | — | — | — |
| 36 | BioRestorative Therapies Developer of stem cell therapies to address multiple diseases 27News top 24%Moat top 32%Funding top 33%Patents top 42% All 11 signals ▾Newstop 24% Moattop 32% Fundingtop 33% Patentstop 42% Growthtop 43% Techtop 45% Innovationbottom 48% Globalbottom 41% Talentbottom 40% Fin. healthbottom 26% Marketbottom 21% News: 9 BI events in 12 mo (of 27 tracked, 6 types) · +80% YoY Moat: Editorial + unicorn rating 4/10 · IP moat: 45 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $20M | 8 mo ago | 10 10 → 21 (+110%) · sector median +32% | Lance Alstodt Chairman and CEO | WordPressMySQLPHP+25 | 9 signals ▲80% Funding · Earnings · Leadership | 45 patents Patents concentrated in chemistry & materials | — |
| 37 | Ambrosia Biosciences Developer of small molecule-based therapies for metabolic disorders | $16M | 2 mo ago | — | Nick Traggis Founder & CEO | WordPressMySQLPHP+16 | — | — | — |
| 38 | Rejuvenate Bio Developer of gene therapies for treating chronic and age-related diseases | $15M | 23 mo ago | 39 | Noah Davidsohn Co-Founder & CSO | Cart FunctionalitySquarespace CommerceSquarespace+12 | — | — | — |
| 39 | Bloom Science Developer of therapies to treat neurological diseases | $12M | 14 mo ago | 26 | Christopher Reyes CEO | — | — | — | — |
| 40 | Anagram Developer of therapeutics for metabolic diseases | $8M | 1 mo ago | 20 | Robert Gallotto President and Chief Executive Officer | — | — | — | — |
| 41 | Oxalo Therapeutics Developing innovative therapeutics for rare kidney diseases and recurrent kidney stones | $7M | 16 mo ago | 2 | Hatim Hassan Co-Founder | — | — | — | — |
| 42 | Rila Therapeutics Provider of therapeutics for the treatments for kidney fibrosis | $7M | 17 mo ago | — | John He Co-Founder | — | — | — | — |
| 43 | Remedy Plan Developing first-in-class NAMPT inhibitors for oncology, autoimmune, and metabolic diseases | $7M | 13 mo ago | 10 | — | Craft CMSPHPYii+10 | — | 24 patents Small‑molecule oncology drugs targeting cancer stem cells and NAMPT enzymes | — |
| 44 | Senseion Therapeutics Developer of therapeutics for the treatment of metabolic diseases | $6M | 15 mo ago | — | Rajan Sah Co-Founder | — | — | — | — |
| 45 | Mitotherapeutix Developer of small molecules based drug using siRNA technology for various diseases | $5M | 15 mo ago | 5 | Robert Hemley Co-Founder & COO | — | — | 8 patents Targeted multivalent ligand drug delivery and epigenetic J‑protein expression inhibition | — |
| 46 | Halo Biosciences Developer of therapies by editing extracellular matrix | $5M | 14 mo ago | 12 | Andy Wardle Co-Founder & Advisor | — | — | — | — |
| 47 | Tega Therapeutics Glycoscience company developing heparan sulfate therapies and enzyme replacement therapy | $4M | 6 mo ago | 7 | — | — | — | — | — |
| 48 | Bfkw Satiety induction through gastric implant | $4M | 19 mo ago | 4 | — | — | — | 164 patents Intraluminal medical device fixation and deployment systems for minimally invasive procedures. | — |
| 49 | Mercury Bio Developer of nanoparticle-based drug delivery systems 8Funding top 50%Talent bottom 49%Global bottom 25%News bottom 22% All 5 signals ▾Fundingtop 50% Talentbottom 49% Globalbottom 25% Newsbottom 22% Marketbottom 20% Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 8/100 | $4M | 8 mo ago | 6 | Bruce McCormick CEO | — | — | — | — |
| 50 | Vogenx Developer of therapeutics for the treatment of serious metabolic and gastrointestinal diseases | $750K | 6 mo ago | — | James Green Chief Executive Officer | — | — | 9 patents Patents concentrated in health & consumer products | — |
Top 12 Metabolic Diseases companies in United States
#1
Series D · Berkeley Heights, New Jersey · founded 2019$287Mraised▾
Series D · Berkeley Heights, New Jersey · founded 2019
Developer of therapies for patients with cardiometabolic conditions. It offers a pipeline of treatments including an oral small molecule GLP-1 receptor agonist for the treatment of obesity and diabetes mellitus, JX10 is an investigational drug for acute ischemic stroke, and JX09 a next-generation highly selective aldosterone synthase inhibitor for hypertension, heart failure and chronic kidney disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Funding rounds
- Jan 2026Series D$287M
Founders & team
Investors
SR One, TCG Crossover, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management
Tech stack
CloudflareCloudflare Browser InsightsCloudflare Rocket LoaderGoogle Font ApiHstsHttp/3
#2
Enveda 🦄Series D · Boulder, Colorado · founded 2019$504.8Mraised▾
Enveda 🦄
Series D · Boulder, Colorado · founded 2019
AI-based platform to decipher the chemistry of nature and develop new medicines. It employs advanced computational methods, high throughput automation, and metabolomics to identify potential treatments for various diseases. It leverages chemical knowledge of nature to accelerate drug discovery and development.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 12%Moat
top 32%Growth
top 35%Market
top 44%AI
top 45%Talent
bottom 49%Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Series D (Sep 2025)
Moat: Unicorn · 10 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Funding rounds
- Sep 2025Series D$150M
- Feb 2025Series C—
- Nov 2024Series C$130M
- Jun 2024Series B$55M
Founders & team
Investors
SVB, FPV Ventures, JAZZ Venture Partners, Level Ventures, Amino Collective, Allen & Company
Tech stack
Apple Icloud MailBootstrapCloudflareCloudflare Bot ManagementCore-JsCrazy Egg
#3
Public · Waltham, Massachusetts · founded 2024$400Mraised▾
Public · Waltham, Massachusetts · founded 2024
Developer of therapies for treating obesity and related conditions. It offers a pipeline of drug candidates which include KAI-9531 a GLP-1/GIP receptor dual agonist formulated as an injectable peptide, KAI-7535 is an oral small molecule, KAI-9531 is a GLP-1/GIP receptor, and KAI-9531 is a GLP-1/GIP receptor for the treatment of obesity and type 2 diabetes.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 12%Growth
top 20%News
top 22%Moat
top 31%Tech
top 40%Talent
bottom 41%Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series B (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
News: 6 BI events in 12 mo (of 6 tracked, 2 types) · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO, Leadership
Audience (LinkedIn): 17k LinkedIn followers — 4.4% of this cohort's audience
Funding rounds
- Oct 2025Series B$600M
- Oct 2024Series A$400M
Founders & team
Investors
Atlas Venture, Bain Capital Life Sciences, RTW Investments, Bain Capital Private Equity, Adage Capital Management, CPP Investments
Tech stack
AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#4
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#5
Public · Menlo Park, California · founded 2018 · 196 employees$120Mraised▾
Public · Menlo Park, California · founded 2018 · 196 employees
Developer of small molecule based therapeutics to treat rare diseases. The company's lead product candidate Maralixibat inhibits a carrier protein called apical sodium-dependent bile acid transporter for reducing systemic levels of bile acids. It is used for the treatment of both Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis. The other product of the company Volixibat is used for the treatment of adult cholestasis.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Funding
top 17%Patents
top 18%Innovation
top 23%Product
top 28%Growth
top 30%Fin. health
top 31%Funding: Raised $120M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Post IPO (Jan 2026)
Patents: 135 patents matched (strict assignee match) · 115 filings since 2022 vs 20 in 2017-21 · Latest publication 2026
Innovation: 135 patents (top 21% of patent-holders) · 115 filings since 2022 vs 20 in 2017-21
Audience (LinkedIn): 47k LinkedIn followers — 12.0% of this cohort's audience
Funding rounds
- Jan 2026Post IPO$68.5M
- Dec 2020Post IPO$10M
- Nov 2018Series A$120M
Founders & team
Investors
New Enterprise Associates, Deerfield, Frazier Healthcare Partners, Novo Holdings, Pappas Capital, Rock Springs Capital
Tech stack
CloudflareCloudflare Bot ManagementCookieyesDocusignGodaddyGoogle Analytics
#6
Public · Wellesley, Massachusetts · founded 2009 · 252 employees$150.5Mraised▾
Public · Wellesley, Massachusetts · founded 2009 · 252 employees
Developer of Gastric Balloon device for weight loss management. The Program targets obesity by combining a gastric balloon that occupies stomach space to promote fullness with behavioral coaching and an app for tracking progress.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 22%Customers
top 23%Product
top 24%Tech
top 26%Moat
top 38%Market
top 40%Funding: Raised $151M across 15 rounds · 15 rounds over 14 yrs (1.1/yr) · Last round Post IPO (Nov 2025)
Customers: Play-Store rating 4.75★ across 1,421 ratings (1 apps) · Review volume +53% in 6 mo
Product: 4 distinct product lines · 1 published app (95.4k installs) · Company stage: Public
Audience (LinkedIn): 50k LinkedIn followers — 12.9% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Nov 2025Post IPO$5M
- Jan 2025Post IPO$2.5M
- Apr 2024Post IPO$48M
- Dec 2023Post IPO$122.5K
Founders & team
Investors
Novalis LifeSciences, Romulus Capital, IDO Investments, Bridge Bank, RTW Investments, Cogepa
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesApache Http ServerApple Icloud MailAws Certificate Manager
#7
Series A · Dallas, Texas · founded 2018 · 8 employees$22.1Mraised▾
Series A · Dallas, Texas · founded 2018 · 8 employees
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Mar 2026Series B$250K
- Nov 2024Series B$20.4M
- Oct 2019Seed$1.5M
Founders & team
Investors
Maryland Momentum Fund, Parent Project Muscular Dystrophy, RA Capital Management, USM
Tech stack
CloudflareCloudflare Bot ManagementDiviGodaddyGodaddy CoblocksGoogle Analytics
#8
Series A · Kalamazoo, Michigan · founded 2015 · 11 employees$75.2Mraised▾
Series A · Kalamazoo, Michigan · founded 2015 · 11 employees
Developer of therapeutics to treat liver and metabolic diseases. The company's lead product is MSDC-0602K, a second-generation insulin sensitizer for the treatment of NASH. It has the potential to reduce metabolic dysregulation that insulin resistance and tissue damage.
Funding rounds
- Oct 2025Series A$800K
- Oct 2024Series A$1M
- Jul 2024Series A$1.3M
- May 2019Series A$7.5M
Investors
Frazier Healthcare Partners, Adams Street Partners, Renaissance Venture Capital Fund, Novo Holdings, Hopen Life Science Ventures, Frazier Life Sciences
#9
Series B · Boulder, Colorado · founded 2024$16Mraised▾
Series B · Boulder, Colorado · founded 2024
Developer of small molecule-based therapies for metabolic disorders. It offers an enzyme technology platform that converts obesity-promoting sugars into minimal-calorie rare sugars to treat obesity.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Funding rounds
- Mar 2026Series B$100M
- Jul 2024Series A$16M
Founders & team
Investors
BVF Partners, Boulder Ventures, Blue Owl Healthcare Opportunities, Redmile Group, Deep Track Capital, Janus Henderson Investors
Tech stack
Animate.CssAosBootstrapCloudflareCloudflare Bot ManagementCore-Js
#10
Series B · Natick, Massachusetts · founded 2017 · 20 employees$8.2Mraised▾
Series B · Natick, Massachusetts · founded 2017 · 20 employees
Developer of therapeutics for metabolic diseases. It offers orally-delivered enzymes as therapies for malabsorption syndrome and nutrient metabolism disorders which is s caused by enzyme deficiencies or genetic mutations.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- May 2026Series B$250M
- Aug 2022Grant (prize money)$1.8M
- Jan 2018Grant (prize money)$3M
- Aug 2017Series A$8.2M
Founders & team
Investors
Cystic Fibrosis Foundation, HHS, Blackstone
#11
Series A · Boulder, Colorado · founded 2019 · 21 employees$26Mraised▾
Series A · Boulder, Colorado · founded 2019 · 21 employees
Provider of synthetic biology platform to develop small-molecule therapeutics. The company's platform combines applied microbiology, enzymology, and data science to develop medicines against difficult-to-drug proteins.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 30%Talent
top 38%Moat
top 39%Global
bottom 39%Tech
bottom 30%Market
bottom 28%Funding: Raised $26.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Series A (Jan 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Jan 2026Series A$55M
- May 2024Seed$6M
- Aug 2022Seed$17M
- Dec 2020Grant (prize money)$255.9K
Founders & team
Investors
America’s Seed Fund, Innovation Endeavors, Xora Innovation, AV8 Ventures, Buff Gold Ventures, LiquidMetal Ventures
#12
Acquired · Irvine, California · founded 2017 · 11 employees$140Mraised▾
Acquired · Irvine, California · founded 2017 · 11 employees
Developer of therapeutics for gout, chronic kidney diseases, and oncology. The company's proprietary drug candidate includes AR882 which is used to decrease the level of uric acid in gout patients. It works by inhibiting urate transporter 1 (URAT1), an influx transporter protein present in kidneys.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 26%News
top 46%Moat
top 48%Talent
bottom 49%Tech
bottom 43%Global
bottom 37%Funding: Raised $140M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Series E (Jun 2025)
News: 2 BI events in 12 mo (of 6 tracked, 3 types) · +100% YoY · Top themes: M&A, Funding
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Funding rounds
- Jun 2025Series E$153M
- Jul 2023Series D$75M
- Mar 2023Series B$15M
- Nov 2021Series B$26M
Founders & team
Investors
Guangrun Health Industry, Reichstein Biotech, Prime Eight Capital, Hlc Fund, HM Venture Partners, Reliant Tech
Tech stack
Animate.CssAosApple Icloud MailBootstrapBootstrap IconsCloudflare
Funding & investor landscape
$14.3Btotal disclosed funding
208companies funded
914disclosed rounds
3rounds last 90 days
Most active investors
SVB8 rounds
Notable founders
Sandy Mou
CEO · CORXEL
Viswa Colluru
Founder & CEO · Enveda
Ron Renaud
Founder & CEO · Kailera
Shankar Ramaswamy
Co-Founder & CEO · Kriya Therapeutics
Roger Jeffs
Co-Founder · Kriya Therapeutics
Christopher Peetz
CEO · Mirum Pharmaceuticals
Samuel Levy
Founder · Allurion
Sudhish Sharma
Co-Founder · Secretome Therapeutics
Muthukumar Gunasekaran
Co-Founder · Secretome Therapeutics
Nick Traggis
Founder & CEO · Ambrosia Biosciences
Robert Gallotto
President and Chief Executive Officer · Anagram
Jerome Fox
Co-Founder & CEO · Think Bioscience
Prism market signals · United States · country-scoped Prism corpus, 11,894,684 docs
Market landscape — 10 sub-themes by coverage
Share of Metabolic Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research surged from 33 to 164 papers, now dominating the segment alongside newly emerging functional-biology topics.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements intensified sharply — each rising from ~3 to 62 papers — as fermentation and probiotics newly emerge.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern papers tripled from 15 to 45, while integrated pest management and animal health risks are newly flagged.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
How many Metabolic Diseases companies are there in United States?
Radar tracks 296 indexable Metabolic Diseases companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Metabolic Diseases companies in United States?
The Metabolic Diseases companies in United States on this list have raised a combined $14.3B in disclosed equity funding across 208 funded companies.
Which is the highest-funded Metabolic Diseases company in United States?
Nimbus Therapeutics is the highest-funded Metabolic Diseases company in United States, with $637M in disclosed equity funding.
How many Metabolic Diseases companies in United States are funded?
208 of the 296 Metabolic Diseases companies in United States on this list have disclosed at least one equity funding round.
How many Metabolic Diseases unicorns are there in United States?
1 Metabolic Diseases company in United States on this list is valued at $1B or more.
Who are the top investors in United States Metabolic Diseases companies?
The most active investors in United States Metabolic Diseases companies on this list include HHS, RA Capital Management, Frazier Healthcare Partners, Orbimed, 5AM Ventures.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.